Alexander Ploss

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2070727/publications.pdf

Version: 2024-02-01

		57758	46799
96	8,400	44	89
papers	citations	h-index	g-index

98	98	98	11365
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation. Journal of Hepatology, 2022, 76, 1229-1231.	3.7	5
2	Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2112008119.	7.1	7
3	Î¼Map-Red: Proximity Labeling by Red Light Photocatalysis. Journal of the American Chemical Society, 2022, 144, 6154-6162.	13.7	42
4	Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection. Cell Reports, 2022, 39, 110714.	6.4	14
5	Rise above the stressâ€"Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles. Hepatology, 2022, 75, 248-251.	7.3	0
6	Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. Nature Communications, 2022, 13, .	12.8	11
7	Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells. JHEP Reports, 2022, 4, 100534.	4.9	6
8	Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90. Antiviral Research, 2021, 185, 104997.	4.1	15
9	Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nature Communications, 2021, 12, 1591.	12.8	53
10	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. ELife, 2021, 10, .	6.0	160
11	Animal Models for Hepatitis B: Does the Supply Meet the Demand?. Gastroenterology, 2021, 160, 1437-1442.	1.3	4
12	Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Microâ€scalable Hepatic Coâ€culture System. Hepatology, 2020, 71, 14-30.	7.3	31
13	Master of Disguise: Hepatitis Delta Virus Packaging and Spread Facilitated by Diverse Viral Envelope Proteins. Hepatology, 2020, 71, 380-382.	7.3	5
14	Identification of Plasmodium falciparum proteoforms from liver stage models. Malaria Journal, 2020, 19, 10.	2.3	2
15	Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	10.3	23
16	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Current HIV Research, 2020, 18, 19-28.	0.5	9
17	Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nature Microbiology, 2020, 5, 715-726.	13.3	70
18	Woolly Monkeyâ€"HBV Infection in Squirrel Monkeys as a Surrogate Nonhuman Primate Model of HBV Infection. Hepatology Communications, 2020, 4, 371-386.	4.3	11

#	Article	IF	Citations
19	Hepatitis E Virus Replication. Viruses, 2019, 11, 719.	3.3	40
20	Decoding type I and III interferon signalling during viral infection. Nature Microbiology, 2019, 4, 914-924.	13.3	353
21	Conservation of cell-intrinsic immune responses in diverse nonhuman primate species. Life Science Alliance, 2019, 2, e201900495.	2.8	6
22	Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus. ELife, 2019, 8, .	6.0	10
23	The use of humanized mice for studies of viral pathogenesis and immunity. Current Opinion in Virology, 2018, 29, 62-71.	5.4	27
24	A porcine model for chronic hepatitis E. Hepatology, 2018, 67, 787-790.	7.3	1
25	Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses. Nature Communications, 2018, 9, 5031.	12.8	39
26	Identification of the Intragenomic Promoter Controlling Hepatitis E Virus Subgenomic RNA Transcription. MBio, 2018, 9, .	4.1	35
27	Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Science Translational Medicine, 2018, 10, .	12.4	34
28	Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6310-E6318.	7.1	137
29	Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe. Trends in Microbiology, 2018, 26, 913-928.	7.7	123
30	A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism. PLoS Pathogens, 2018, 14, e1006908.	4.7	20
31	Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1147-1152.	7.1	171
32	Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. Journal of Hepatology, 2017, 67, 246-254.	3.7	52
33	Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology, 2017, 502, 63-72.	2.4	16
34	Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo. Journal of Virology, 2017, 91, .	3.4	22
35	Long-term hepatitis B infection in a scalable hepatic co-culture system. Nature Communications, 2017, 8, 125.	12.8	58
36	Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo. MBio, 2017, 8, .	4.1	52

#	Article	IF	Citations
37	Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers in Cell and Developmental Biology, 2016, 4, 64.	3.7	45
38	In vivo models of hepatitis B and C virus infection. FEBS Letters, 2016, 590, 1987-1999.	2.8	22
39	Flunarizine prevents hepatitis C virus membrane fusion in a genotypeâ€dependent manner by targeting the potential fusion peptide within E1. Hepatology, 2016, 63, 49-62.	7.3	64
40	Generation of Human Liver Chimeric Mice for the Study of Human Hepatotropic Pathogens. Methods in Molecular Biology, 2016, 1438, 79-101.	0.9	3
41	Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Current Opinion in Virology, 2016, 20, 1-10.	5.4	47
42	Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. Journal of Virology, 2016, 90, 10486-10498.	3.4	68
43	Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. New England Journal of Medicine, 2016, 375, 220-228.	27.0	67
44	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. MBio, 2016, 7, .	4.1	13
45	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519, 87-91.	27.8	265
46	Study of viral pathogenesis in humanized mice. Current Opinion in Virology, 2015, 11, 14-20.	5.4	16
47	Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4. MBio, 2015, 6, e02518.	4.1	15
48	Determinants of hepatitis B and delta virus host tropism. Current Opinion in Virology, 2015, 13, 109-116.	5.4	23
49	Modeling malaria in humanized mice: opportunities and challenges. Annals of the New York Academy of Sciences, 2015, 1342, 29-36.	3.8	27
50	Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice. Hepatology, 2015, 62, 57-67.	7.3	22
51	Proteomic approaches to analyzing hepatitis C virus biology. Proteomics, 2015, 15, 2051-2065.	2.2	6
52	Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. Annual Review of Genetics, 2015, 49, 21-45.	7.6	35
53	Novel Biomarkers Associated With the Outcome of Interferon-Based Hepatitis C Virus Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 257-258.	4.5	1
54	Editorial overview: Progress and challenges in modeling human viral diseases in vivo. Current Opinion in Virology, 2015, 13, v-vii.	5.4	0

#	Article	IF	Citations
55	Insufficient interleukinâ€12 signalling favours differentiation of human CD4⁺ and <scp>CD</scp>8⁺ T cells into <scp>GATA</scp>â€3⁺ and <scp>GATA</scp>â€3⁺ÂTâ€bet⁺ subsets in humanized mice. Immunology, 2014, 143, 202-218.	4.4	22
56	Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. Journal of Biological Chemistry, 2014, 289, 35015-35028.	3.4	17
57	Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Science Translational Medicine, 2014, 6, 254ra129.	12.4	204
58	Murine models of hepatitis C: What can we look forward to?. Antiviral Research, 2014, 104, 15-22.	4.1	27
59	Interferon Lambda Alleles Predict Innate Antiviral Immune Responses and Hepatitis C Virus Permissiveness. Cell Host and Microbe, 2014, 15, 190-202.	11.0	94
60	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut, 2014, 63, 1137-1149.	12.1	148
61	The Impact of Hepatitis C Virus Entry on Viral Tropism. Cell Host and Microbe, 2014, 16, 562-568.	11.0	74
62	Utility of Humanized BLT Mice for Analysis of Dengue Virus Infection and Antiviral Drug Testing. Journal of Virology, 2014, 88, 2205-2218.	3.4	51
63	Mouse models for human infectious diseases. Journal of Immunological Methods, 2014, 410, 1-2.	1.4	5
64	Visualizing hepatitis C virus infection in humanized mice. Journal of Immunological Methods, 2014, 410, 50-59.	1.4	15
65	Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature, 2013, 501, 237-241.	27.8	205
66	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	7.1	247
67	Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2013, 7, 171-185.	3.0	12
68	Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature Medicine, 2013, 19, 730-738.	30.7	134
69	Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model. Journal of Virology, 2013, 87, 8535-8544.	3.4	24
70	Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice. Journal of Immunology, 2013, 191, 1753-1764.	0.8	64
71	A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15859-15864.	7.1	75
72	Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14610-14615.	7.1	166

#	Article	IF	Citations
73	C7L Family of Poxvirus Host Range Genes Inhibits Antiviral Activities Induced by Type I Interferons and Interferon Regulatory Factor 1. Journal of Virology, 2012, 86, 4538-4547.	3.4	39
74	Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2544-2548.	7.1	197
75	Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6205-6210.	7.1	306
76	Hepatitis C virus host cell entry. Current Opinion in Virology, 2012, 2, 14-19.	5.4	79
77	Development of humanized mouse models to study human malaria parasite infection. Future Microbiology, 2012, 7, 657-665.	2.0	54
78	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	27.8	463
79	Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. Journal of Clinical Investigation, 2012, 122, 3618-3628.	8.2	200
80	A genetically humanized mouse model for hepatitis C virus infection. Nature, 2011, 474, 208-211.	27.8	331
81	Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice. Journal of Hepatology, 2011, 54, 848-850.	3.7	5
82	Development of human CD4+FoxP3+ regulatory T cells in human stem cell factorâ€“, granulocyte-macrophage colony-stimulating factorâ€“, and interleukin-3â€“expressing NOD-SCID IL2RÎ³null humanized mice. Blood, 2011, 117, 3076-3086.	1.4	267
83	Deconstructing hepatitis C virus infection in humanized mice. Annals of the New York Academy of Sciences, 2011, 1245, 59-62.	3.8	5
84	Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology, 2011, 54, 1901-1912.	7.3	80
85	Hepatitis C virus induces interferon-Î» and interferon-stimulated genes in primary liver cultures. Hepatology, 2011, 54, 1913-1923.	7.3	157
86	Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nature Biotechnology, 2010, 28, 167-171.	17.5	235
87	Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3141-3145.	7.1	187
88	Splicing Diversity of the Human OCLN Gene and Its Biological Significance for Hepatitis C Virus Entry. Journal of Virology, 2010, 84, 6987-6994.	3.4	33
89	Advances and challenges in studying hepatitis C virus in its native environment. Expert Review of Gastroenterology and Hepatology, 2010, 4, 541-550.	3.0	19
90	New horizons for studying human hepatotropic infections. Journal of Clinical Investigation, 2010, 120, 650-653.	8.2	46

#	Article	IF	Citations
91	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. Journal of Experimental Medicine, 2009, 206, 1423-1434.	8.5	269
92	The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response. Journal of Immunology, 2009, 183, 7919-7930.	0.8	296
93	Towards a small animal model for hepatitis C. EMBO Reports, 2009, 10, 1220-1227.	4.5	69
94	Humanized Mice for Modeling Human Infectious Disease: Challenges, Progress, and Outlook. Cell Host and Microbe, 2009, 6, 5-9.	11.0	202
95	Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 2009, 457, 882-886.	27.8	813
96	Pathogen-Specific CD8 T Cell Responses Are Directly Inhibited by IL-10. Journal of Immunology, 2007, 179, 4520-4528.	0.8	47